Research programme: glycogen synthase kinase 3 inhibitors - Kinetek

Drug Profile

Research programme: glycogen synthase kinase 3 inhibitors - Kinetek

Alternative Names: Research programme: GSK-3 inhibitors - Kinetek

Latest Information Update: 18 Aug 2006

Price : $50

At a glance

  • Originator Kinetek Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 31 Dec 2005 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
  • 02 Apr 2004 Kinetek Pharmaceuticals has been acquired by QLT
  • 23 Aug 2000 Preclinical development for Cancer in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top